# A Study of APD356 (Lorcaserin) in Healthy Japanese Adult Subjects

> **NCT02192515** · PHASE1 · COMPLETED · sponsor: **Eisai Co., Ltd.** · enrollment: 40 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** APD356 10 mg
- **DRUG:** APD356 XR-20 mg
- **DRUG:** APD356 10 mg matching Placebo
- **DRUG:** APD356 XR-20 mg matching Placebo
- **DRUG:** APD356 20 mg
- **DRUG:** APD356 20 mg matching Placebo
- **DRUG:** APD356 XR-20 mg (orange tablet)
- **DRUG:** APD356 XR-20mg (orange tablet, fed state)

## Key facts

- **NCT ID:** NCT02192515
- **Lead sponsor:** Eisai Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2015-11
- **Final completion:** 2016-01
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2016-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02192515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02192515, "A Study of APD356 (Lorcaserin) in Healthy Japanese Adult Subjects". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02192515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*